2022.08.30

Allurion Technologies

Segulah Medical Acceleration Announces Investment in Allurion Technologies

2022.09.13

Segulah Medical Acceleration AB (“SMA”) has made a minority investment in US-based Allurion Technologies during their July 2021 extension of the $34m Series D financing. The Series D round was led by Novalis LifeSciences and Romulus Capital.

Read more

Segulah Medical Acceleration Announces Investment in Navinci Diagnostics

2022.07.12

Navinci Diagnostics AB, a Swedish life science company developing innovative tools for spatial proteomics research, announces the closing of SEK 90 million financing. The round was led by Segulah Medical Acceleration (”SMA”), a Scandinavia-based life science-focused investment company, together with existing shareholders, including Landegren Gene Technology AB, Nexttobe AB, and Beijer Ventures AB.

Read more

Signifier Medical Technologies is granted HCPCS Codes

2022.02.28

Signifier Medical Technologies is granted HCPCS Codes for eXciteOSA to help patients access innovative technology

Read more

Segulah Medical Acceleration Announces Investment in Signifier Medical Technologies

2021.07.30

Segulah Medical Acceleration AB (SMA) announced today that it has invested in UK-based Signifier Medical Technologies’ USD 35 million Series D convertible financing. The financing was jointly led by SMA together with Angelus Venture Fund I L.P., Alan Howard (co-founder of Brevan Howard Asset Management) and Pioneer Healthcare Partners LP.

Read more

Segulah Medical Acceleration Announces Investment in SAGA Diagnostics

2021.06.30

Segulah Medical Acceleration AB (SMA) announced today that it has invested in cancer liquid biopsy and genomic testing company SAGA Diagnostics’ oversubscribed SEK 106 million (€10.5 million) Series A2 equity financing round. The round was led by SMA together with the Sciety investment syndicate with strong support from existing shareholders such as Hadean Ventures.

Read more

Segulah Medical Acceleration Announces Investment in Quanta Dialysis Technologies

2021.06.28

Segulah Medical Acceleration AB (SMA) a specialized growth equity investment firm focused on Medtech and related areas, announced today that it has invested in Quanta Dialysis Technologies oversubscribed and upsized $245 million Series D equity financing round. This financing is the largest ever private funding round for a dialysis device company.

Read more

Blue chip investors back new MedTech investment company

2021.04.29

Segulah Medical Acceleration, SMA, is a newly formed company specializing in medical technology investments, with a focus on Sweden, Scandinavia and Western Europe. The company is financed by leading institutions and prominent private investors, whose initial commitments amount to approximately SEK 1.2 billion.

Read more